As Congress considers lowering drug costs, pharma CEOs target key senators with campaign cash

“Instead, the executives are using their considerable personal wealth to fund GOP lawmakers playing key roles in the Senate’s ongoing consideration of a bill to lower drug costs, which is projected to cost drug companies $85 billion in revenue in the next decade.”

https://www.statnews.com/2019/09/03/pharma-executives-campaign-donations-influential-gop-senators/